Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
642 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01018745 | Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan | completed | Phase 1 | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 7, 2011 | clinicaltrials |
| NCT00482703 | A Study of Dasatinib in Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia | completed | Phase 1 / Phase 2 | 23 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 17, 2010 | clinicaltrials |
| NCT00339144 |
| Study of Dasatinib (BMS-354825) in Patients With Solid Tumors |
| completed |
| Phase 1 |
| 16 |
| Bristol-Myers SquibbINDUSTRY |
| 1 |
| Dec 15, 2010 |
| clinicaltrials |
| NCT01030718 | Rollover Study of BMS-354825 in Patients With CML and Ph+ALL | completed | Phase 1 / Phase 2 | 54 | Bristol-Myers SquibbINDUSTRY | 0 | Dec 14, 2010 | clinicaltrials |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | unknown | Phase 2 | 72 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT00768911 | CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 1 | 30 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT00101816 | Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate | completed | Phase 2 | 124 | Bristol-Myers SquibbINDUSTRY | 20 | Aug 10, 2010 | clinicaltrials |
| NCT00103844 | Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 32 | Aug 10, 2010 | clinicaltrials |
| NCT00298467 | MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma | withdrawn | Phase 2 | 45 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 26, 2010 | clinicaltrials |
| NCT00729950 | Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 92 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00928031 | Long-term Data Collection for Subjects in MDX-010 Studies(MDX010-28) | completed | — | 160 | Bristol-Myers SquibbINDUSTRY | 1 | Apr 26, 2010 | clinicaltrials |
| NCT00730652 | Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma(MDX1411-02) | withdrawn | Phase 1 | 34 | Bristol-Myers SquibbINDUSTRY | 0 | Apr 22, 2010 | clinicaltrials |
| NCT00036621 | A Randomized, Placebo-Controlled Trial of BMS-275291 Given Daily for 12 Months to Women With Stage 1c-IIIA Breast Cancer Receiving Adjuvant Chemotherapy and/or Hormonal Therapy | terminated | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00095537 | BMS-599626 in Patients With Advanced Solid Malignancies | completed | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00099879 | Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer | terminated | Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 7 | Mar 2, 2010 | clinicaltrials |
| NCT00101608 | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 150 | Bristol-Myers SquibbINDUSTRY | 15 | Mar 2, 2010 | clinicaltrials |
| NCT00103831 | Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | — | Bristol-Myers SquibbINDUSTRY | 2 | Mar 2, 2010 | clinicaltrials |
| NCT00207012 | MAD Refractory: Solid Tumor QD w/o Break | completed | Phase 1 | 45 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 2, 2010 | clinicaltrials |
| NCT00207025 | A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies | terminated | Phase 1 | 60 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 2, 2010 | clinicaltrials |
| NCT00289640 | Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma | completed | Phase 2 | 210 | Bristol-Myers SquibbINDUSTRY | 10 | Mar 2, 2010 | clinicaltrials |
| NCT00300027 | Study of BMS-582664 in Combination With Either FOLFIRI or FOLFOX for Gastrointestinal (GI) Malignancies | terminated | Phase 1 | 50 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00326131 | A Phase I Study of a Single Dose of Radio-labeled BMS-275183 in Patients With Advanced Cancer | terminated | Phase 1 | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 2, 2010 | clinicaltrials |
| NCT00332748 | A Phase I Study of BMS-275183 (Oral Taxane) Given on a Daily Schedule in Combination With Esomeprazole (Nexium) in Patients With Advanced Cancer | terminated | Phase 1 | 36 | Bristol-Myers SquibbINDUSTRY | 2 | Mar 2, 2010 | clinicaltrials |
| NCT00359450 | Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer) | terminated | Phase 2 | 186 | Bristol-Myers SquibbINDUSTRY | 8 | Mar 2, 2010 | clinicaltrials |
| NCT00359476 | A Study of Vinflunine in Patients With Gastric Cancer | terminated | Phase 2 / Phase 3 | 55 | Bristol-Myers SquibbINDUSTRY | 3 | Mar 2, 2010 | clinicaltrials |
| NCT00298987 | A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate | completed | Phase 2 | 400 | Bristol-Myers SquibbINDUSTRY | 2 | Feb 8, 2010 | clinicaltrials |
| NCT00990912 | A Study to Document Long-Term Safety and Continued Benefit of Irinotecan and Carboplatin or Irinotecan in Subjects With Refractory Solid Tumors (Rollover Study -001, -002) | completed | Phase 1 / Phase 2 | 20 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 5, 2010 | clinicaltrials |
| NCT00337532 | A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer | completed | Phase 2 / Phase 3 | 50 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 4, 2010 | clinicaltrials |
| NCT00855764 | Late Phase II Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Head and Neck Cancer | completed | Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 4, 2010 | clinicaltrials |
| NCT01023204 | Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Breast Cancer | completed | Phase 2 | 68 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 4, 2010 | clinicaltrials |
| NCT00080509 | Effectiveness of KOS-862 in the Treatment of Lung Cancer | terminated | Phase 2 | 85 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 3, 2010 | clinicaltrials |
| NCT00362466 | A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy | terminated | Phase 3 | 3 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 20, 2009 | clinicaltrials |
| NCT00344552 | Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer | completed | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00351325 | A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies | terminated | Phase 1 | 45 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 4, 2009 | clinicaltrials |
| NCT00461110 | A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC) | terminated | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 4, 2009 | clinicaltrials |
| NCT00374179 | CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma | completed | Phase 1 | 40 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Feb 24, 2009 | clinicaltrials |
| NCT00435669 | A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) | completed | Phase 1 | 4 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 22, 2009 | clinicaltrials |
| NCT00030173 | A Trial to Evaluate Epothilone D in Patients With Advanced Solid Tumors | completed | Phase 1 | 45 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 8, 2009 | clinicaltrials |
| NCT00207103 | MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors | completed | Phase 1 | 68 | Bristol-Myers SquibbINDUSTRY | 4 | Nov 4, 2008 | clinicaltrials |
| NCT00516451 | Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors | completed | Phase 1 | 9 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 13, 2008 | clinicaltrials |
| NCT00104130 | Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer | terminated | Phase 2 | 53 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 17, 2008 | clinicaltrials |
| NCT00578916 | Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects | completed | Phase 1 | 17 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 31, 2008 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials